Close Menu
News JournosNews Journos
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
Facebook X (Twitter) Instagram
Latest Headlines:
  • Nvidia’s Jensen Huang Courts Beijing Amid Renewed Market Access in China
  • Volcanic Eruption in Iceland Forces Evacuation of Tourists from Blue Lagoon as Lava Approaches Grindavik
  • Humanity Faces Significant Losses, Says Spokesperson
  • Gun Seller Backed by Donald Trump Jr. Launches Stock Trading
  • Lightning Strike in New Jersey Leaves 1 Dead, 13 Injured
  • Used EV Batteries Poised to Power AI Growth
  • UK Inflation Data Reveals Key Trends for June
  • Hijacked Small Plane Grounds Flights at Vancouver International Airport
  • Experts Warn of Vulnerabilities in Federal E-Verify System Following Workplace Raids
  • Trial Commences Over Alleged Facebook Privacy Violations Involving CEO and Others
  • Controversy Surrounds Franco-Israeli Singer Amir at Francofolies de Spa Festival
  • Newsom Criticizes Trump’s National Guard Move, Urges Maturity
  • Potential Consequences of Trump’s Dismissal of Fed Chair Powell
  • Prince Harry Honors Diana’s Legacy by Advocating Against Landmines in Angola
  • Tsunami Warning Lowered to Advisory Following 7.2 Magnitude Earthquake near Alaska
  • Goldman Sachs Reports Q2 2025 Earnings Results
  • Rubio Calls Israeli Strike on Damascus a ‘Misunderstanding’ Amid Peace Efforts
  • Complete Skeleton of Medieval Knight Discovered Beneath Former Ice Cream Parlor in Poland
  • James Gunn Discusses “Superman”: Release Date, Character’s Immigrant Story, and Themes of Kindness
  • Assembly Discusses Olive Grove; Tanal’s Brief Action Sparks Varank’s Controversial Remarks
Facebook X (Twitter) Instagram
News JournosNews Journos
Subscribe
Thursday, July 24
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
News JournosNews Journos
Trump to Sign Order on Most Favored Nation Drug Pricing

Trump to Sign Order on Most Favored Nation Drug Pricing

News EditorBy News EditorMay 12, 2025 Business 6 Mins Read

President Donald Trump is set to reinstate a contentious policy aimed at reducing drug costs by aligning U.S. prices with lower rates abroad. This initiative, known as the “most favored nation” policy, will be formalized through an executive order that encompasses various actions. Officials from the White House emphasized that the administration is committed to alleviating the financial burden of prescription medications on American patients, as many struggle with high costs.

Article Subheadings
1) Overview of the “Most Favored Nation” Policy
2) Expected Impact on the Pharmaceutical Industry
3) Implications for Patients and Drug Prices
4) Challenges and Controversies Surrounding the Policy
5) Future Prospects for Drug Pricing Reforms

Overview of the “Most Favored Nation” Policy

The “most favored nation” policy aims to reduce the amount the U.S. government pays for prescription drugs by tying these costs to lower prices available in other countries. This initiative demonstrates a significant shift in U.S. healthcare policy, reflecting a broader commitment to tackle issues of drug affordability that plague American consumers. The executive order that Trump is expected to sign includes a variety of actions meant to broaden the scope of this policy compared to previous attempts in his administration.

While specific medications targeted by this order remain undisclosed, officials indicated that the focus will primarily be on high-cost drugs that exhibit significant price disparities and represent a considerable portion of healthcare expenditures. This approach aims to level the playing field and ensure that Americans do not bear a disproportionate cost burden compared to patients in other countries.

Expected Impact on the Pharmaceutical Industry

The announcement of this policy has already elicited a negative response from several major pharmaceutical companies. In premarket trading, shares of numerous drug manufacturers, including Eli Lilly and Pfizer, saw declines, reflecting investor concerns regarding potential profit losses. Many industry executives argue that implementing the “most favored nation” policy could undermine their financial capacity to fund research and development for new medications and treatments.

Interestingly, the Pharmaceutical Research and Manufacturers of America (PhRMA) estimated that the Medicaid proposal could cost drug manufacturers about $1 trillion over a decade. Such projections highlight the potentially substantial ramifications of this policy on the financial landscape of the pharmaceutical sector, leading to an ongoing debate about balancing patient affordability and incentivizing innovation.

Implications for Patients and Drug Prices

For American patients, the implementation of this policy could have significant implications. Currently, more than three-quarters of U.S. adults consider the cost of medications unaffordable, as revealed in a 2022 KFF poll. The expectation is that, by tying U.S. drug prices to those abroad, patients will experience reduced costs for essential medications, particularly in areas like diabetes treatments and weight loss drugs.

Officials assert that the policy could lead to drug price reductions of up to 59%, as announced by Trump in a recent social media post. However, the actual effectiveness of this policy remains uncertain, with health policy experts cautioned that it may not adequately address the fundamental economic realities of the global drug marketplace. Despite the promise of potential savings, the road ahead could be turbulent, encapsulated by industry pushback and possible legal challenges.

Challenges and Controversies Surrounding the Policy

While the “most favored nation” policy appears geared toward enhancing patient access and affordability, it does not come without its challenges. Legal battles may loom as pharmaceutical companies express resistance, reflecting a historical trend of the industry lobbying against similar initiatives. The last attempt at implementing this policy faced judicial setbacks, ultimately being rescinded by the Biden administration.

Moreover, the dynamics of international drug pricing complicate the policy’s implementation. Unlike the U.S., many countries with universal healthcare possess the leverage to negotiate drug prices effectively. As a result, U.S. companies often find themselves in vulnerable positions during negotiations, would likely face pressure to make concessions that could affect profitability.

Future Prospects for Drug Pricing Reforms

Looking ahead, the administration appears determined to maintain its stance on lowering drug costs, buoyed by public demand for reforms. One of the key elements of the order also instructs the Secretary of the Department of Health and Human Services to set clear price reduction targets within a specified timeline. This demand for accountability may steer negotiations between the HHS and pharmaceutical companies, providing a structured framework for monitoring progress.

Additionally, ongoing market conditions and shifts in public sentiment surrounding drug pricing are likely to influence these reforms. With drug price negotiations now a key provision under the Inflation Reduction Act, Trump‘s administration may not only push the boundaries of executive action but also navigate a complex legislative landscape filled with varying stakeholder interests.

No. Key Points
1 President Trump is reviving the “most favored nation” policy to reduce drug costs.
2 The policy ties U.S. drug prices to lower international rates, targeting significant disparities.
3 Pharmaceutical stocks have already dropped in response to the announcement.
4 Experts express skepticism regarding the policy’s potential effectiveness in lowering costs.
5 The administration is prepared for possible legal challenges from the pharmaceutical industry.

Summary

In sum, Trump‘s revival of the “most favored nation” policy signifies a strong pivot toward taming the high costs associated with U.S. prescription drugs. As the administration navigates uncharted waters filled with industry pushback and legal implications, the overarching goal remains to ensure that patients gain equitable access to affordable medication. The coming months will be crucial for assessing the effectiveness of this policy and its impact on American healthcare.

Frequently Asked Questions

Question: What is the “most favored nation” policy?

The “most favored nation” policy ties the prices the U.S. pays for prescription drugs to the lower prices offered in other countries, aiming to reduce costs for American consumers.

Question: How will this policy affect pharmaceutical companies?

Pharmaceutical companies may face reduced profits and increased pressure during negotiations, which could affect their ability to fund research and development for new drugs.

Question: Is there evidence that this policy will successfully lower drug prices?

Experts are skeptical about the policy’s effectiveness, suggesting that it may not address the fundamental economic dynamics of the global pharmaceutical marketplace.

Business Ethics Business Growth Business News Business Technology Consumer Trends Corporate Finance Corporate Strategy drug Economic Outlook Entrepreneurship Favored Global Business Innovation Investment Opportunities Leadership Management Market Trends Mergers & Acquisitions Nation order Pricing Retail Business sign Small Business Startups Supply Chain Trump
News Editor
  • Website

As the News Editor at News Journos, I am dedicated to curating and delivering the latest and most impactful stories across business, finance, politics, technology, and global affairs. With a commitment to journalistic integrity, we provide breaking news, in-depth analysis, and expert insights to keep our readers informed in an ever-changing world. News Journos is your go-to independent news source, ensuring fast, accurate, and reliable reporting on the topics that matter most.

Keep Reading

Business

Media Landscape Changes Drive Emergence of New Leadership

6 Mins Read
Business

Stock and Sales Decline Amid CEO Brian Cornell’s Termination

6 Mins Read
Business

Rolls-Royce Invests $75 Million to Expand South Carolina Manufacturing Facility

5 Mins Read
Business

WNBA’s Portland Fire Reveals Name and Logo Before 2026 Season

5 Mins Read
Business

Tariffs Impacting Office Recovery Efforts

6 Mins Read
Business

Real Estate Firms Compete to Establish Lunar Data Centers and Support Infrastructure

6 Mins Read
Mr Serdar Avatar

Serdar Imren

News Director

Facebook Twitter Instagram
Facebook X (Twitter) Instagram Pinterest
  • About Us
  • Get In Touch
  • Privacy Policy
  • Accessibility
  • Terms and Conditions
© 2025 The News Journos. Designed by The News Journos.

Type above and press Enter to search. Press Esc to cancel.